Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Hanmi Pharma GLP-1 drug to get edge in South Korea obesity market due to local trials, says GlobalData

The Korean Ministry of Food and Drug Safety (MFDS) has recently given clearance to Hanmi Pharmaceutical to conduct Phase III trial for its Korean-optimized obesity candidate efpeglenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Against this backdrop, efpeglenatide is expected to get an edge in the domestic obesity market due to local trials, says GlobalData, a […]
Read more

Positive post hoc analysis of SCORED trial to bolster Inpefa use for heart failure, says GlobalData

At this year’s American Heart Association Scientific Session, positive results were presented from Lexicon Pharmaceuticals’ SCORED analysis of Inpefa (sotagliflozin), providing insight into the drug’s ability to significantly reduce the risk of heart failure (HF) in as little as three months. The post hoc analysis could be of high clinical value to cardiologists looking to […]
Read more

Sugemalimab approval in China makes it only second drug approved globally for ENKTL, says GlobalData

CStone Pharmaceuticals’ sugemalimab (Cejemly) has been approved by the China National Medical Products Administration (NMPA) for the treatment of relapsed or refractory extranodal natural killer/T-cell lymphoma (r/r ENKTL) in October 2023. With this approval, sugemalimab becomes the first anti-PD-1/PD-L1 monoclonal antibody approved for r/r ENKTL globally and is expected to boost CStone’s presence in the […]
Read more

Oncology KRAS-targeting therapy market to exceed $4 billion by 2029, forecasts GlobalData

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are common in solid tumors, including lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The introduction of KRAS inhibitors has become a significant advancement in the quickly developing area of oncology, providing hope in the battle against difficult solid tumors. The global market for KRAS-targeting drugs in […]
Read more

Arrowhead Pharmaceuticals’ plozarsiran and zodasiran hold potential to treat dyslipidemia, says GlobalData

At the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Arrowhead Pharmaceuticals unveiled the Phase II clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3). The Phase II SHASTA-2 study showed that plozasiran decreased APOC3 to -79%, triglycerides (TGs) to -74%, remnant cholesterol to -65% and increased high-density lipoprotein (HDL)-cholesterol (HDL-C) to 68% at 24 […]
Read more

Vertex Pharmaceuticals poised for dominance in global gene therapy market with first CRISPR approval, says GlobalData

Following the news that the UK Medicines and Healthcare Products Regulatory Agency has granted conditional marketing authorization to Vertex Pharmaceuticals and CRISPR Therapeutics‘ Casgevy, marking the world’s first approval of a CRISPR-based gene editing therapy; Joselia Carlos, Medical Device Analyst at GlobalData, offers her view: “The approval of Casgevy for sickle cell anemia (SCA) and […]
Read more

FDA’s Fast Track designation for Altimmune’s pemvidutide reinforces use of GLP-1RAs in NASH, says GlobalData

In October 2023, the FDA granted Fast Track designation for Altimmune’s incretin mimetic, pemvidutide, in non-alcoholic steatohepatitis (NASH). Pemvidutide is a glucagon-like peptide 1 (GLP-1) glucagon receptor (GCGR) dual agonist peptide (GLP-1R/GCGR) currently in Phase IIb development for NASH (IMPACT trial) and for obesity (MOMENTUM trial). The Fast Track designation is supported by the data […]
Read more

Vast majority of healthcare professionals believed that COVID-19 had greatest impact on digital transformation, reveals GlobalData survey

Globally, 71% of healthcare industry professionals expressed that the COVID-19 pandemic had the greatest impact on digital transformation in the healthcare sector during the last few years, among other macro events, according to a survey* by GlobalData, a leading data and analytics company. GlobalData’s latest Thematic Intelligence report, ‘Digital Transformation and Emerging Technologies in the […]
Read more

First-in-class DLL3-targeting BiTE could be the next big player in small-cell lung cancer treatment, says GlobalData

Small cell lung cancer (SCLC), comprising 15% of lung tumors, is a highly aggressive form of malignancy. However, tarlatamab, a bispecific T-cell engager (BiTE) developed by Amgen, recently demonstrated potentially registrational data at the European Society for Medical Oncology (ESMO) 2023 Congress from the Phase II DeLLphi-301 trial.  The drug may become a promising lifeline […]
Read more
1 … 26 27 28 29 30 … 108